Category: Legal News
The U.S. Justice Dept. closes a years-long probe into Medtronic's controversial Infuse bone growth protein, weight-loss surgeries may trigger a rare metabolic wasting disease and the renal denervation space becomes a battle ground for med-tech titans vying for rank.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
The U.S. Justice Dept. closes its years-long criminal and civil investigation into Medtronic's controversial Infuse bone growth protein.
The U.S. Justice Dept. closed the books on a years-long investigation into Medtronic's (NYSE:MDT) controversial Infuse bone growth protein, the company announced today.
The office of the U.S. Attorney for the District of Massachusetts and the DoJ abandoned their civil and criminal probe into allegations of off-label marketing and concealed safety risks without finding evidence of wrongdoing, according to a press release.
Just weeks before a $2.3 billion acquisition by Asahi Kasei closed, the Securities & Exchange Commission shut the books on a review of Zoll Medical's sales to Iran, Syria and other countries the U.S. deems "state sponsors of terrorism."
An unsealed whistleblower lawsuit accuses Medtronic of violating the Medicare False Claims Act through illegal marketing of its Infuse bone growth protein, alleging that the medical device maker installed a crony as editor of an influential spine journal to push positive data on the controversial compound.
A whistleblower accused Medtronic (NYSE:MDT) of installing a stooge, spinal surgeon Dr. Thomas Zdeblick, as editor of an influential spine journal to push positive – and possibly premature – data on its Infuse bone growth stimulant.
A group of Kensey Nash shareholders sue to block the $360 million Royal DSM merger; RyMed and ICU Medical declare victory against each other; a California judge frees Lap-Band patients from forced arbitration; and hearing aid maker HearUSA confirms bankruptcy.
Kensey Nash shareholders sue to block Royal DSM merger
Riata's survival rates called "significantly worse" in an independent study, DePuy may be showing its hand in defending its recalled metal-on-metal hips ahead of court hearings and Covidien denies a widely disseminated rumor that it cut 200 workers to offset the cost of the medical device tax.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Dr. Mark Midei, accused of implanting stents in hundreds of patients who didn't need them, lost a bid to reinstate his medical license back; also, Coloplast claims victory against Generic Medical Devices in patent spat and Cordis pursues subpoenas in stent lawsuit against Abbott.
Maryland denies accused over-stenter's bid to reclaim medical license
